Imatinib is one outstanding example which is used in the treatment of chronic myelogenous leukemia (CML) with a significant therapeutic effect by specifically inhibiting tyrosine kinases BCR-ABL, c-KIT, and PDGFRA (Iurlo et al., 2015). The gene discussed is PDGFRA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.